Abstract

HMG - COA REDUCTASE INHIBITORS ASSOCIATED WITH REDUCED MORTALITY IN ESRD PATIENTS ON DIALYSIS

Tejomurthula Himasree*, Ganjimala Sukanya, Padamati Lakshmi Prasanna, Kantimohanthu Madhavi, Sadasivarao Galaba

ABSTRACT

Cardiovascular disease is the most common cause of mortality in patients with end-stage renal disease. Patients with end-stage renal disease are mainly suffer from the higher rates cardiovascular diseases when compared to general population. For example, among patients treated by hemodialysis or peritoneal dialysis, the prevalence of coronary artery disease is approximately 40% and the prevalence of left ventricular hypertrophy is approximately 75%. Cardiovascular mortality has been estimated to be approximately 9% per year. Although therapy with 3-hydroxy-3-methylglutaryl coenzyme A (HMG - Co A) reductase inhibitors (“statin’s”) has been demonstrated to reduce the mortality from cardiovascular disease in patients without ESRD, only 10% of patients on dialysis are treated with these medications by day 60 of ESRD. This study determined whether the use of statins is associated with reduction in cardiovascular- specific deaths and mortality in ESRD patients

Keywords: .